Wild-type (senile) amyloidosis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 19: | Line 19: | ||
:*[[Troponin I]] or [[Troponin T]] | :*[[Troponin I]] or [[Troponin T]] | ||
:*[[Brain natriuretic peptide|BNP]] and [[NT-proBNP]] | :*[[Brain natriuretic peptide|BNP]] and [[NT-proBNP]] | ||
=== Nervous === | |||
* In the case of CNS involvement (carpal tunnel syndrome), the following tests should be ordered for confirmation of the presenting symptoms: | |||
** [[Electromyography|Electromyography (EMG)]] and [[Nerve conduction studies|nerve conduction studies (NCS)]] | |||
==References== | ==References== | ||
Revision as of 21:55, 17 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis laboratory findings |
|
Wild-type (senile) amyloidosis laboratory findings in the news |
|
Risk calculators and risk factors for Wild-type (senile) amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Laboratory Findings
- Wild-type (senile) amyloidosis is a diagnosis of exclusion.
- Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition.
- The absence of AL amyloid provides a strong clue towards the diagnosis of wild-type (senile) amyloidosis.
Cardiac
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
- They provide a quantitative assessment for cardiac damage and wall strain.[1]
- The biomarkers include:
- Troponin I or Troponin T
- BNP and NT-proBNP
Nervous
- In the case of CNS involvement (carpal tunnel syndrome), the following tests should be ordered for confirmation of the presenting symptoms:
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.